Positive Recommendation on Nuvectis Pharma Driven by Promising Lead Candidate and Milestone Clinical Studies
I'm PortAI, I can summarize articles.
Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating for Nuvectis Pharma, with a $10.00 price target. The recommendation is driven by promising clinical studies of NXP900, targeting advanced EGFR-mutated NSCLC. The Phase 1b study, broad enrollment criteria, and promising Phase 1a results enhance the stock's outlook. Expected data readouts in 2026 could further support the positive outlook.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments